{
    "clinical_study": {
        "@rank": "148008", 
        "arm_group": {
            "arm_group_label": "Treatment (CPI-613)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive CPI-613 IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies CPI-613 (6,8-bis[benzylthio]octanoic acid) in treating\n      patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the\n      growth of tumor cells and may be an effective treatment for small cell lung cancer."
        }, 
        "brief_title": "CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer", 
        "condition": "Recurrent Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the safety and anti-cancer activities in patients with relapsed or refractory\n      small cell lung cancer (SCLC) who have failed 1 or 2 lines of chemotherapy.\n\n      OUTLINE:\n\n      Patients receive CPI-613 intravenously (IV) over 2 hours on days 1 and 4 of weeks 1-3.\n      Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 2 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically proven SCLC that has relapsed or been refractory from\n             at least one line of chemotherapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 3\n\n          -  Expected survival > 1 month\n\n          -  No acute toxicities from previous treatment higher than grade 1 at the start of\n             treatment with CPI-613\n\n          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not\n             surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine\n             device [IUD], oral contraceptive or double barrier device) during the study, and must\n             have a negative serum or urine pregnancy test within 1 week prior to treatment\n             initiation\n\n          -  Men must practice effective contraceptive methods during the study, unless\n             documentation of infertility exists\n\n          -  Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L\n\n          -  Absolute neutrophil count (ANC) >= 1500 cells/mm^3 or >= 1.5 bil/L\n\n          -  Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3\n             x upper normal limit (UNL)\n\n          -  Bilirubin =< 1.5 x UNL\n\n          -  Serum creatinine =< 1.5 mg/dL or 133 \u00b5mol/L\n\n          -  Albumin > 2.0 g/dL or > 20 g/L\n\n          -  Mentally competent, ability to understand and willingness to sign an Institutional\n             Review Board (IRB)-approved written informed consent form\n\n          -  Have access via central line (e.g., portacath)-double lumen due to CPI-613\n             administration requirements\n\n        Exclusion Criteria:\n\n          -  Patients receiving any other standard or investigational treatment for their cancer,\n             or any investigational agent for any non-cancer indication within the past 2 weeks\n             prior to initiation of CPI-613 treatment\n\n          -  Serious medical illness that would potentially increase patients' risk for toxicity\n\n          -  Any active uncontrolled bleeding or bleeding diathesis\n\n          -  Pregnant women, women of child-bearing potential not using reliable means of\n             contraception, or lactating women\n\n          -  Men unwilling to practice contraceptive methods during the study period\n\n          -  Life expectancy less than 1 month\n\n          -  Treatment with any anti-cancer therapy within the 2 weeks prior to treatment with\n             CPI-613\n\n          -  Patients with untreated central nervous system (CNS) or epidural tumor\n\n          -  Any condition or abnormality which may, in the opinion of the investigator,\n             compromise his or her safety\n\n          -  Unwilling or unable to follow protocol requirements\n\n          -  Active heart disease including myocardial infarction within previous 6 months,\n             symptomatic coronary artery disease, arrhythmias not controlled with medication, or\n             symptomatic congestive heart failure\n\n          -  Evidence of active infection or serious infection (e.g., septic shock with\n             multi-organ dysfunction) within the past month\n\n          -  Patients with known human immunodeficiency virus (HIV) infection\n\n          -  Requirement for immediate palliative treatment of any kind including surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931787", 
            "org_study_id": "CCCWFU 62113", 
            "secondary_id": [
                "NCI-2013-01653", 
                "CCCWFU 62113", 
                "P30CA012197"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Treatment (CPI-613)", 
            "description": "Given IV", 
            "intervention_name": "6,8-bis(benzylthio)octanoic acid", 
            "intervention_type": "Drug", 
            "other_name": [
                "alpha-lipoic acid analogue CPI-613", 
                "CPI-613"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Thioctic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "contact": {
                "email": "jruiz@wakehealth.edu", 
                "last_name": "Jimmy Ruiz", 
                "phone": "336-716-4464"
            }, 
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Comprehensive Cancer Center of Wake Forest University"
            }, 
            "investigator": {
                "last_name": "Jimmy Ruiz", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Small Cell Lung Carcinoma (SCLC)", 
        "other_outcome": {
            "description": "Each toxicity identified in the protocol will be examined by grade.", 
            "measure": "Incidence of toxicities, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 3 years"
        }, 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "Jimmy Ruiz", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of responders as the percent of patients who are SD, PR and CR will be estimated, as well as RR (sum of PR + CR) and disease control rate (DCR, which is the sum of SD, PR and CR). 95% confidence intervals will be included.", 
            "measure": "Tumor response rates, defined as the proportion of patients who achieve complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD)", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931787"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Survival curves for PFS will be estimated using Kaplan-Meier techniques. In addition, the 6 month and 1-year PFS rates will be estimated. Median PFS will be estimated as well.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Survival curves for OS will be estimated using Kaplan-Meier techniques. In addition, the 6 month and 1-year OS rates will be estimated. Median OS will be estimated as well.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Comprehensive Cancer Center of Wake Forest University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Comprehensive Cancer Center of Wake Forest University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}